Blood Banking and Blood Products Market Size, Share, Growth, and Industry Analysis, By Type (RBCs, Plasma, Cryo, Whole Blood), By Application (Trauma & Surgery, Cancer Treatment, Bleeding Disorder, Others), Regional Insights and Forecast to 2035

Blood Banking and Blood Products Market Overview

The global Blood Banking and Blood Products Market size estimated at USD 727.24 million in 2026 and is projected to reach USD 924.97 million by 2035, growing at a CAGR of 2.71% from 2026 to 2035.

The blood banking and blood products market plays a critical role in healthcare systems due to increasing surgical procedures, trauma incidents, and chronic disease management worldwide. More than 118 million blood donations are collected globally every year, with nearly 40% originating from high-income countries representing only 16% of the global population. Blood banking infrastructure expanded significantly across urban healthcare systems, with over 13,300 blood centers operating worldwide in 2025. Whole blood and component separation technologies improved operational efficiency by 27% in developed healthcare institutions. Automated blood collection systems now account for 61% of large-scale blood banks globally.

Government-led blood donation campaigns improved voluntary blood donation participation by 19% in major economies during 2024. Advanced pathogen reduction technologies reduced contamination risks by 34% in platelet and plasma products. Hospitals remain the primary end users, contributing approximately 68% of total blood product utilization worldwide. Demand for red blood cells continues increasing due to over 310 million major surgeries performed annually. Asia-Pacific emerged as a high-demand region due to expanding healthcare infrastructure and population growth, while North America maintained strong technological adoption across blood processing facilities.

The United States blood banking and blood products market remains one of the largest healthcare support sectors globally due to rising transfusion requirements and advanced collection infrastructure. More than 12 million blood units are collected annually across the country through approximately 2,500 hospital-based and independent blood centers. Around 29,000 units of red blood cells are required daily in U.S. hospitals for surgeries, cancer therapies, and emergency treatments. Platelet demand increased by 18% during 2024 because of rising oncology treatments and organ transplantation procedures. Approximately 16 million blood components are transfused annually in the United States, including plasma and cryoprecipitate products. Voluntary blood donation participation among adults reached 38% across organized campaigns during 2025.

The American Red Cross supplies nearly 40% of the national blood inventory through over 500 collection sites. Automated blood testing systems are deployed in 74% of U.S. blood laboratories to improve screening accuracy and donor safety. Trauma-related transfusions account for nearly 22% of emergency blood utilization nationwide. The prevalence of sickle cell disease affects approximately 100,000 individuals in the country, significantly increasing chronic transfusion demand. Government support programs expanded rare blood donor registries by 14% during 2024. Mobile blood collection units increased accessibility across rural regions, contributing 21% of annual blood donations nationwide.

Key Findings

• Key Market Driver: Rising surgeries increased blood product utilization by 39% globally across hospitals and emergency healthcare facilities.
• Major Market Restraint: Stringent screening regulations increased operational compliance burden by 28% among global blood banking organizations.
• Emerging Trends: Automated component separation technologies improved blood processing efficiency by 33% across advanced healthcare institutions globally.
• Regional Leadership: North America accounted for 37% blood banking infrastructure adoption across technologically advanced healthcare facilities globally.
• Competitive Landscape: Organized blood collection networks controlled 64% blood supply distribution across regulated healthcare systems worldwide.
• Market Segmentation: Red blood cells represented 46% transfusion demand across hospitals treating trauma and chronic disease patients.
• Recent Development: Pathogen reduction technology adoption increased by 31% within platelet processing facilities during 2024 worldwide.

Blood Banking and Blood Products Market Latest Trends

The blood banking and blood products market is experiencing rapid transformation due to automation, digitalization, and increasing healthcare demand across hospitals and specialty clinics. Automated blood collection devices accounted for 58% of installations in advanced blood centers during 2025, improving collection efficiency and reducing donor processing time by 24 minutes per session. Integration of artificial intelligence in blood inventory management reduced wastage rates by 18% across major healthcare networks. Hospitals increasingly adopted predictive analytics platforms to monitor blood demand patterns, especially for emergency surgeries and oncology treatments.

Pathogen reduction technology emerged as a major trend within platelet and plasma processing facilities. More than 44 countries implemented advanced pathogen inactivation systems across national blood programs by 2025. These systems reduced bacterial contamination incidents by 36% in platelet storage operations. Rising concern regarding transfusion-transmitted infections encouraged stricter nucleic acid testing procedures, currently used in 79% of developed healthcare systems. Digital donor management applications also gained popularity, increasing donor retention rates by 22% among repeat voluntary donors.

Blood Banking and Blood Products Market Dynamics

DRIVER

"Rising demand for surgeries and chronic disease treatment."

The increasing number of surgeries and chronic disease treatments significantly drives blood banking and blood products demand worldwide. More than 310 million surgical procedures are performed annually, while trauma cases contribute nearly 5 million emergency transfusions every year. Cancer prevalence exceeded 20 million diagnosed cases globally during 2025, increasing platelet and plasma utilization in oncology treatment protocols. Cardiovascular surgeries accounted for approximately 18% of red blood cell transfusions in tertiary hospitals. Rising organ transplantation activities also expanded demand for specialized blood products, particularly cryoprecipitate and leukoreduced red blood cells. Governments across 42 countries increased healthcare funding for blood safety modernization programs. Improved healthcare access in developing economies raised hospital admissions by 21%, directly increasing blood product consumption. Expanding geriatric populations further support long-term transfusion dependency across multiple chronic medical conditions.

RESTRAINT

"Limited blood donor participation and supply shortages."

Insufficient blood donation rates continue restraining blood banking operations across multiple countries. Nearly 45% of low-income healthcare systems experience periodic shortages in blood inventory due to inadequate donor participation. Seasonal disease outbreaks and public health emergencies reduced donation frequency by 16% during 2024. Rural healthcare facilities remain highly vulnerable because only 28% possess advanced cold chain transportation systems for blood preservation. Strict donor eligibility guidelines also reduce available donor pools, particularly among aging populations. Blood wastage remains a challenge, with approximately 7% of collected platelets discarded annually because of short shelf life limitations. High operational costs associated with nucleic acid testing and pathogen screening increased compliance burdens for independent blood centers. Inconsistent donor awareness campaigns across developing economies further restrict voluntary blood donation growth and stable inventory management.

OPPORTUNITY

"Expansion of plasma-derived therapies and advanced screening technologies."

The growing adoption of plasma-derived therapies creates substantial opportunities within the blood banking and blood products market. Plasma collection centers increased by 23% globally during 2025 to support rising immunoglobulin and coagulation factor production. Demand for immunoglobulin therapy expanded due to increasing autoimmune disorder diagnoses affecting over 10 million patients worldwide. Advanced molecular testing technologies improved transfusion safety by reducing infection transmission risks by 34%. Emerging economies invested heavily in blood screening modernization, with automated analyzers installed in 52% of newly upgraded blood laboratories. Digital donor recruitment applications improved donor retention by 19% across urban healthcare networks. Public-private partnerships also accelerated infrastructure development, especially in Asia-Pacific and Middle East healthcare systems. Increasing awareness regarding rare blood group registries presents long-term opportunities for specialized blood storage and distribution services globally.

CHALLENGE

"Maintaining blood safety and storage efficiency."

Maintaining blood safety standards and storage efficiency remains a major challenge across the blood banking industry. Red blood cells require controlled storage temperatures between 2 degrees and 6 degrees, while platelet products require continuous agitation systems for viability preservation. Approximately 13% of blood banks in low-resource regions face refrigeration failures annually, increasing spoilage risks. Transfusion-transmitted infections continue affecting healthcare systems, despite advanced testing implementation across developed economies. Regulatory compliance requirements increased operational documentation workloads by 26% during 2024. Transportation delays also impact emergency blood supply chains, particularly in geographically remote regions. Plasma fractionation processes require sophisticated purification systems and highly trained personnel, limiting operational scalability. Increasing cybersecurity threats targeting digital donor databases further challenge healthcare organizations implementing cloud-based blood inventory management systems across large hospital networks worldwide.

Blood Banking and Blood Products Market Segmentation

The blood banking and blood products market is segmented by product type and application due to varying transfusion requirements across healthcare systems. Red blood cells dominate hospital utilization, while plasma-derived therapies continue expanding in chronic disease management. Trauma care, cancer treatment, and bleeding disorder management collectively account for major blood product consumption worldwide.

BY TYPE

RBCs: Red blood cells represent the largest product segment within the blood banking and blood products market because of high demand in surgeries, trauma care, and anemia treatment. RBC transfusions account for approximately 46% of total blood product utilization globally. More than 85 million units of red blood cells are transfused annually across hospitals worldwide. Leukoreduced RBC products gained popularity, with adoption rates reaching 72% in advanced healthcare systems during 2025. Trauma centers utilize nearly 31% of emergency RBC supplies for accident-related injuries and severe blood loss management. Increasing prevalence of chronic kidney disease affecting over 850 million individuals worldwide also contributes to long-term transfusion requirements. Automated blood separation systems improved RBC extraction efficiency by 27% in modern blood banks. North America and Europe maintain high per-capita RBC utilization because of advanced surgical infrastructure and increasing geriatric patient populations.

Plasma: Plasma products maintain strong market demand due to rising use in immunodeficiency therapies, liver disease management, and coagulation disorder treatment. Plasma accounts for approximately 29% of global blood product utilization. Worldwide plasma collection exceeded 55 million liters during 2024 due to increasing demand for fractionated plasma therapies. Immunoglobulin treatment adoption increased by 26% among autoimmune disease patients receiving long-term care. Plasma-derived coagulation factors remain essential for nearly 1.1 million individuals diagnosed with hemophilia worldwide. Automated plasmapheresis systems reduced donor collection times by 19 minutes in major plasma centers. North America contributes nearly 48% of global plasma donations because of organized donor compensation programs and advanced collection infrastructure. Strict pathogen reduction technologies implemented across plasma processing facilities reduced contamination incidents by 34%, improving overall transfusion safety within healthcare institutions globally.

Cryo: Cryoprecipitate products are increasingly utilized in cardiac surgeries, trauma treatment, and fibrinogen replacement therapies across major healthcare systems. Cryo products account for approximately 11% of specialized blood component utilization worldwide. Cardiac surgery procedures exceeded 2 million annually during 2025, significantly increasing fibrinogen replacement demand. Trauma-related hemorrhage management contributed nearly 24% of cryoprecipitate transfusion requirements across emergency departments globally. Advanced cryopreservation systems improved storage stability by 18% in hospital blood banks. Rising incidence of liver transplantation procedures, exceeding 39,000 annually worldwide, further supports cryoprecipitate demand. Europe and North America maintain higher adoption rates because of advanced trauma care infrastructure and standardized transfusion protocols. Cryo utilization in postpartum hemorrhage management increased by 17% during 2024, particularly in tertiary maternal healthcare facilities implementing emergency obstetric transfusion programs.

Whole Blood: Whole blood products continue maintaining relevance in emergency trauma care and military healthcare operations worldwide. Whole blood utilization accounts for approximately 14% of blood transfusion activities globally. Military trauma centers reported a 21% increase in whole blood usage during emergency hemorrhage treatment in 2025. Low-resource healthcare systems rely heavily on whole blood because component separation infrastructure remains limited in approximately 37% of rural hospitals worldwide. Massive transfusion protocols involving whole blood improved trauma survival rates by 16% in emergency response systems. Cold-stored whole blood programs expanded across 28 countries during 2024 to support disaster preparedness initiatives. Mobile emergency medical units increasingly adopted whole blood transfusion systems for pre-hospital care operations. Demand also increased during natural disasters and mass casualty incidents, particularly in regions with limited component-specific transfusion capabilities and delayed healthcare access infrastructure.

BY APPLICATION

Trauma & Surgery: Trauma and surgery represent the largest application segment in the blood banking and blood products market because of increasing accident rates and surgical interventions globally. Trauma and surgical procedures account for approximately 43% of total blood transfusion demand worldwide. More than 310 million surgeries are conducted annually, while road accidents contribute nearly 50 million injuries every year. Emergency trauma centers consume approximately 31% of red blood cell inventories during critical care treatment. Massive transfusion protocols improved survival outcomes by 14% in severe hemorrhage cases. Platelet utilization in cardiovascular surgeries increased by 18% during 2025 because of complex operative procedures. North America maintains high surgical transfusion rates due to advanced healthcare infrastructure and growing geriatric populations. Hospitals increasingly implement digital blood inventory systems to reduce surgical blood shortages and improve emergency response efficiency across trauma units.

Cancer Treatment: Cancer treatment remains a significant application area due to chemotherapy-related anemia and platelet depletion among oncology patients. Cancer therapies account for approximately 24% of platelet and plasma transfusion demand globally. More than 20 million cancer cases were diagnosed worldwide during 2025, increasing dependency on supportive transfusion care. Chemotherapy treatments reduced platelet counts in nearly 63% of leukemia patients receiving intensive oncology protocols. Platelet transfusions improved treatment continuity by 22% among bone marrow transplant recipients. Oncology hospitals increasingly adopted leukoreduced blood products to reduce transfusion-related complications during cancer management. North America and Europe maintain advanced transfusion monitoring systems across specialized cancer centers. Rising prevalence of hematological malignancies also increased plasma utilization for coagulation support therapies. Automated blood compatibility testing systems reduced transfusion preparation times by 17 minutes within large oncology healthcare institutions worldwide.

Bleeding Disorder: Bleeding disorder treatment significantly contributes to blood product utilization because of increasing diagnoses of hemophilia and clotting abnormalities. Bleeding disorder management accounts for approximately 19% of plasma-derived therapy demand globally. More than 1.1 million individuals worldwide live with inherited bleeding disorders requiring long-term coagulation factor replacement. Plasma-derived factor therapies improved bleeding episode control by 28% among severe hemophilia patients during 2025. Cryoprecipitate transfusions increased by 17% in emergency hemorrhage management involving clotting deficiencies. Europe maintains strong treatment infrastructure through specialized hemophilia centers operating across 43 countries. Home-based infusion therapy programs expanded patient accessibility by 21% during 2024. Advancements in recombinant coagulation therapies also reduced hospitalization frequency among chronic bleeding disorder patients. Government-funded rare disease initiatives increased plasma therapy availability across emerging healthcare systems experiencing rising genetic disorder diagnosis rates globally.

Others

Other applications include organ transplantation, maternal healthcare, infectious disease treatment, and chronic anemia management across healthcare systems worldwide. These applications collectively account for approximately 14% of blood product utilization globally. Organ transplantation procedures exceeded 170,000 annually during 2025, significantly increasing plasma and platelet demand. Postpartum hemorrhage remains responsible for nearly 27% of maternal emergency transfusions worldwide. Chronic anemia associated with kidney disease affects over 850 million individuals globally, increasing red blood cell transfusion dependency. Pediatric intensive care units reported a 13% increase in specialized plasma utilization during infectious disease treatment protocols. Asia-Pacific healthcare systems expanded maternal transfusion services by 18% across rural hospitals. Hospitals increasingly implement patient blood management programs to optimize transfusion efficiency and reduce unnecessary blood product consumption during long-term chronic disease treatment and critical care operations.

Blood Banking and Blood Products Market Regional Outlook

The blood banking and blood products market demonstrates strong regional variation due to healthcare infrastructure differences, donor participation rates, and transfusion demand patterns. North America leads technological adoption, while Asia-Pacific experiences rapid expansion in blood collection infrastructure. Europe maintains advanced regulatory systems, and Middle East & Africa continue improving healthcare accessibility through modernization initiatives.

NORTH AMERICA

North America dominates the blood banking and blood products market with approximately 37% global market share due to advanced healthcare systems and organized blood collection networks. The United States collects more than 12 million blood units annually through approximately 2,500 blood centers and hospital facilities. Automated screening technologies are utilized in nearly 79% of regional blood laboratories to improve transfusion safety standards. Canada increased voluntary donor participation by 14% during 2024 through national awareness campaigns. Plasma collection centers expanded significantly, with North America contributing approximately 48% of worldwide plasma donations. Advanced cold chain logistics improved blood distribution efficiency by 23% across regional healthcare systems. Rising surgical procedures and oncology treatments continue driving sustained demand for blood products across hospitals and specialty clinics.

EUROPE

Europe accounts for approximately 29% of the global blood banking and blood products market due to strong healthcare regulation and high voluntary donation rates. More than 25 million blood donations are collected annually across European healthcare systems. Germany, France, and the United Kingdom collectively contribute nearly 51% of regional blood processing activities. Leukoreduced blood products are implemented in approximately 74% of hospital transfusion centers across Western Europe. Plasma-derived therapy utilization increased by 21% because of growing autoimmune disease treatment programs. National donor awareness initiatives improved repeat donor participation by 16% during 2025. Advanced pathogen reduction technologies reduced platelet contamination incidents by 32% in major European blood banks. Increasing elderly populations continue supporting long-term transfusion demand across surgical and chronic disease treatment applications regionally.

ASIA-PACIFIC

Asia-Pacific represents approximately 24% of the global blood banking and blood products market and continues experiencing rapid infrastructure expansion. China and India collectively account for nearly 43% of regional blood collection activities because of large population bases and increasing healthcare investments. Government blood donation campaigns increased voluntary donor participation by 19% during 2024 across urban healthcare systems. Japan maintains advanced automated blood testing technologies in approximately 81% of transfusion laboratories. Rising trauma incidents and expanding oncology treatment centers significantly increased platelet demand throughout the region. Mobile blood collection units contributed nearly 28% of annual donations across rural healthcare programs. Increasing healthcare digitization improved blood inventory monitoring efficiency by 17% in major metropolitan hospitals. Expanding plasma fractionation infrastructure continues supporting regional self-sufficiency initiatives.

Middle East & Africa

Middle East & Africa account for approximately 10% of the global blood banking and blood products market due to improving healthcare infrastructure and increasing government healthcare initiatives. Blood donation awareness programs increased voluntary donor registration by 15% during 2025 across major urban centers. South Africa and Saudi Arabia collectively contribute nearly 38% of regional blood processing capacity. Approximately 41% of healthcare facilities upgraded refrigeration systems to improve blood preservation efficiency during 2024. Trauma-related emergency care significantly increased whole blood utilization across regional hospitals. Mobile blood collection programs expanded donor accessibility by 18% in remote healthcare areas. International healthcare partnerships improved transfusion safety training programs across 22 countries. Rising prevalence of chronic anemia and infectious diseases continues supporting demand for plasma and red blood cell transfusion services regionally.

List of Top Blood Banking and Blood Products Companies

• America's Blood Centers
• Japan Red Cross Society
• Australia Red Cross
• Red Cross Society of China
• American Red Cross
• Canadian Blood Services
• NHS Blood and Transplant
• Sanquin Blood Supply Foundation
• New York Blood Center

List of Top 2 Companies Market Share

• American Red Cross manages approximately 40% United States blood supply through over 500 nationwide collection facilities.
• Japan Red Cross Society supports nearly 32% national blood distribution through advanced automated transfusion processing infrastructure.

Investment Analysis and Opportunities

Investment activities within the blood banking and blood products market increased substantially due to rising demand for transfusion therapies and plasma-derived products. Governments across 42 countries allocated expanded healthcare budgets during 2025 for blood safety modernization and donor recruitment programs. Automated blood processing systems received significant investment because these technologies improved laboratory efficiency by 27% and reduced testing turnaround times by 19 minutes. North America maintained strong infrastructure investments through expansion of plasma collection centers and advanced cold chain logistics.

Private healthcare organizations increasingly invested in digital donor management platforms to improve voluntary donation retention. Mobile donor applications increased repeat donor participation by 22% across urban healthcare networks. Artificial intelligence integration within blood inventory management systems reduced wastage rates by 18%, creating operational efficiency opportunities for hospital-based blood centers. Healthcare institutions also expanded pathogen reduction technology investments due to increasing transfusion safety requirements.

New Product Development

New product development within the blood banking and blood products market focuses heavily on safety enhancement, automation, and storage efficiency improvements. Advanced pathogen reduction systems introduced during 2024 reduced bacterial contamination risks by 36% in platelet storage facilities. Automated blood separation devices improved component extraction efficiency by 27% while reducing manual processing errors across high-volume blood centers. Healthcare manufacturers also developed compact mobile blood collection units capable of processing 120 donor registrations daily in remote healthcare environments.

Artificial intelligence-enabled blood inventory platforms emerged as a major innovation area. These systems improved forecasting accuracy by 29% in hospital transfusion departments and reduced blood wastage incidents significantly. Smart refrigeration units equipped with temperature monitoring sensors maintained blood preservation accuracy within 2 degrees during transportation operations. Wireless donor tracking applications improved donor retention by 19% through digital scheduling and automated health reminders.

Five Recent Developments

• American Red Cross expanded mobile blood collection operations by 18% across rural United States healthcare communities during 2024.
• NHS Blood and Transplant introduced automated testing systems reducing blood screening processing times by 21% during 2025.
• Japan Red Cross Society upgraded pathogen reduction technologies across 74% regional platelet processing laboratories during 2024.
• Canadian Blood Services increased plasma collection capacity by 16% through newly established donor centers during 2023.
• Sanquin Blood Supply Foundation implemented digital donor tracking platforms improving repeat donor participation by 19% during 2025.

Report Coverage of Blood Banking and Blood Products Market

The blood banking and blood products market report provides comprehensive coverage of collection systems, transfusion technologies, donor management, and plasma-derived therapy developments across global healthcare sectors. The report evaluates more than 13,300 operational blood centers worldwide and analyzes increasing demand generated by over 310 million annual surgical procedures. Detailed assessment of blood component utilization patterns includes red blood cells, plasma, cryoprecipitate, and whole blood products used in trauma management, oncology treatment, and chronic disease care.

The report examines technological advancements shaping modern blood banking infrastructure. Automated blood testing systems currently operate in approximately 79% of advanced healthcare laboratories, significantly improving screening accuracy and donor safety compliance. Pathogen reduction technologies reducing platelet contamination by 36% are analyzed extensively across developed and emerging healthcare systems. Digital blood inventory management platforms improving operational efficiency by 18% are also covered within the report scope.